Please login to the form below

Not currently logged in
Email:
Password:

Kyprolis

This page shows the latest Kyprolis news and features for those working in and with pharma, biotech and healthcare.

Amgen set for Kyprolis label boost after CHMP backing

Amgen set for Kyprolis label boost after CHMP backing

Amgen set for Kyprolis label boost after CHMP backing. Multiple myeloma treatment set to add new survival data. ... boretezomib). The move was a bit dicey considering Kyprolis’last head-to-head trial with the proteasome inhibitor in 2016 saw it fail to

Latest news

  • Amgen hopes its latest Kyprolis trial hits the mark with regulators Amgen hopes its latest Kyprolis trial hits the mark with regulators

    Sean Harper, executive vice president of research and development, Amgen, said: “Kyprolis has been demonstrated to be the most effective proteosome inhibitor available to patients with multiple myeloma. ... We are encouraged by the efficacy and safety

  • SMC gives green light for Amgen’s Kyprolis SMC gives green light for Amgen’s Kyprolis

    SMC gives green light for Amgen’ s Kyprolis. The committee also gives verdict on three other products. ... Multiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis (carfilzomib

  • SMC gives green light for Amgen’s Kyprolis SMC gives green light for Amgen’s Kyprolis

    SMC gives green light for Amgen’ s Kyprolis. The committee also gives verdict on three other products. ... Multiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis (carfilzomib

  • Amgen aspires to new Kyprolis label in the US and Europe Amgen aspires to new Kyprolis label in the US and Europe

    Newly-released analysis show Kyprolis exceeded its secondary endpoint of overall survival, reducing the risk of death by 21% over Rd alone. ... Patients in the trial received 18 cycles of Kyprolis with Rd administered twice-weekly at 27 mg.

  • FDA halts third Merck myeloma trial after patient deaths FDA halts third Merck myeloma trial after patient deaths

    All patients receiving Keytruda will stop treatment, according to Merck. KEYNOTE-023 is a phase I study looking at Keytruda in combination with standard care - Revlimid, dexamethasone or Amgen's Kyprolis

More from news
Approximately 17 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    drug Kyprolis, acquired in the $10bn purchase of Onyx Pharmaceuticals.

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Indeed it is the fifth-largest biotechnology deal ever. The crown jewel Kyprolis (carfilzomib) is a proteasome inhibitor for the treatment of multiple myeloma which was launched in 2012 and has ... By mid-August only AstraZeneca and Amgen were left

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics